Knowledge Gaps (3383)

Research questions queued for autonomous investigation — enriched with Knowledge Graph context

Quadratic Funding Stats

Gaps Funded
8
Direct Contributions
15536 tokens
Matching Pool
14653 tokens
Total Allocated
30189 tokens

Quadratic funding rewards broad consensus. Formula: match = (Σ √cᵢ)² - Σ cᵢ · API

Research Lifecycle Pipeline

1. Gap Identified
Orchestra detects missing knowledge
2. Investigation
Agents debate & analyze data
3. Hypothesis
Testable claims emerge
4. Mission
Portfolio allocation & funding

Why gaps matter: Each gap represents a strategic opportunity. Filling gaps generates new hypotheses, strengthens evidence networks in the knowledge graph, and improves mission portfolio quality. The system autonomously prioritizes gaps by potential impact, existing KG coverage, and mission alignment.

Showing top 200 of 3383 gaps by priority (3183 more below)

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

BrainDisease

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 17% (2/10 entities, 53.0 edges)
🧬 Hypotheses working on this gap (5 total)
Context-Dependent CRISPR Activation in Specific NeuronaCell-type-specific essential genes27% match
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters20% match
+1 more hypotheses
1.0
UCB: 5.88
📋 0x
partially_addressed
5 hypotheses
✓ Resolved

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

BrainDisease

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 53.0 edges)
🧬 Hypotheses working on this gap (5 total)
Context-Dependent CRISPR Activation in Specific NeuronaCell-type-specific essential genes27% match
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters20% match
+1 more hypotheses
1.0
UCB: 7.34
Repl: 1.46
📋 0x
resolved
5 hypotheses
✓ Resolved

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

BrainDiseaseAlzheimer

What cell types are most vulnerable in Alzheimer's Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 30% (3/10 entities, 5948.0 edges)
🧬 Hypotheses working on this gap (7 total)
Context-Dependent CRISPR Activation in Specific NeuronaCell-type-specific essential genes27% match
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters20% match
+3 more hypotheses
1.0
UCB: 5.88
📋 0x
partially_addressed
7 hypotheses
✓ Resolved

Does TFEB dysfunction causally drive neurodegeneration or represent compensatory response failure?

TFEB

The core causation versus correlation debate remains unresolved despite being central to therapeutic strategy. The distinction determines whether TFEB

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 14% (1/7 entities, 2951.0 edges)
0.9
UCB: 5.85
📋 0x
partially_addressed
✓ Resolved

Senescent cell clearance as neurodegeneration therapy

ParkinsonAlzheimerCNSBBB

Investigate the therapeutic potential of clearing senescent cells (senolytics) to slow or reverse neurodegeneration. Key questions: 1. Which senesce

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 40% (4/10 entities, 9813.0 edges)
🧬 Hypotheses working on this gap (5 total)
+1 more hypotheses
0.9
UCB: 5.85
📋 0x
resolved
5 hypotheses
✓ Resolved

What delivery mechanisms can achieve therapeutically relevant CRISPR concentrations across the blood-brain barrier at scale?

CRISPRSDA-2026-04-02-gap-crispr-neurodegeneration-20260402BBBAAV

All participants identified BBB penetration as a critical bottleneck, but no existing delivery system (AAV, LNPs) achieves sufficient brain distributi

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 36% (4/10 entities, 186.0 edges)
0.9
UCB: 5.85
📋 0x
partially_addressed
✓ Resolved

Neuroinflammation and microglial priming in early Alzheimer's Disease

AlzheimerNeuroinflammationDisease

Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and downstream neurodegeneration in preclinical an

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 75% (3/4 entities, 10588.0 edges)
0.9
UCB: 5.85
📋 0x
partially_addressed
19 hypotheses
✓ Resolved

Immune atlas neuroinflammation analysis in neurodegeneration

TREM2DAM

Comprehensive analysis of immune cell subtypes in neurodegeneration: microglia subtypes (DAM, homeostatic, inflammatory), astrocyte reactivity states,

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 29% (2/7 entities, 3833.0 edges)
0.9
UCB: 5.85
📋 0x
partially_addressed
36 hypotheses
✓ Resolved

Tau propagation mechanisms and therapeutic interception points

Tau

Investigate prion-like spreading of tau pathology through connected brain regions, focusing on trans-synaptic transfer, extracellular vesicle-mediated

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 50% (1/2 entities, 166.0 edges)
🧬 Hypotheses working on this gap (12 total)
Cholesterol-CRISPR Convergence Therapy for NeurodegenerHMGCR, LDLR, APOE regulatory regions30% match
+8 more hypotheses
0.9
UCB: 5.85
📋 0x
partially_addressed
12 hypotheses
✓ Resolved

Cell type vulnerability in Alzheimer's Disease (SEA-AD data)

BrainDiseaseAlzheimer

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data? Use Allen Brain Cell Atlas evidence. Identify mechanism

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 27% (3/10 entities, 5948.0 edges)
🧬 Hypotheses working on this gap (3 total)
Context-Dependent CRISPR Activation in Specific NeuronaCell-type-specific essential genes27% match
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters20% match
0.9
UCB: 5.85
📋 0x
partially_addressed
3 hypotheses
✓ Resolved

Circuit-level neural dynamics in neurodegeneration

Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) corti

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/8 entities, 0 edges)
🧬 Hypotheses working on this gap (8 total)
Cholesterol-CRISPR Convergence Therapy for NeurodegenerHMGCR, LDLR, APOE regulatory regions37% match
Context-Dependent CRISPR Activation in Specific NeuronaCell-type-specific essential genes30% match
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes20% match
+4 more hypotheses
0.9
UCB: 8.11
Repl: 2.26
📋 0x
partially_addressed
8 hypotheses
✓ Resolved

CRISPR-based therapeutic approaches for neurodegenerative diseases

CRISPRALSParkinsonAlzheimerSOD1

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parki

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 59% (10/10 entities, 27221.0 edges)
🧬 Hypotheses working on this gap (18 total)
Trinucleotide Repeat Sequestration via CRISPR-Guided RNHTT, DMPK, repeat-containing transcripts54% match
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters54% match
Programmable Neuronal Circuit Repair via Epigenetic CRINURR1, PITX3, neuronal identity transcription factors34% match
+14 more hypotheses
0.9
UCB: 7.13
Repl: 1.30
📋 0x
partially_addressed
18 hypotheses
✓ Resolved

Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability

BrainAging

What gene expression changes in the aging mouse brain predict neurodegenerative vulnerability? Use Allen Aging Mouse Brain Atlas data. Cross-reference

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 4852.0 edges)
🧬 Hypotheses working on this gap (2 total)
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
0.9
UCB: 5.82
📋 0x
resolved
2 hypotheses
✓ Resolved

Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability

BrainAging

What gene expression changes in the aging mouse brain predict neurodegenerative vulnerability? Use Allen Aging Mouse Brain Atlas data. Cross-reference

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 4852.0 edges)
🧬 Hypotheses working on this gap (2 total)
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
0.9
UCB: 5.82
📋 0x
resolved
2 hypotheses
✓ Resolved

Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability

BrainAging

What gene expression changes in the aging mouse brain predict neurodegenerative vulnerability? Use Allen Aging Mouse Brain Atlas data. Cross-reference

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 4852.0 edges)
🧬 Hypotheses working on this gap (2 total)
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
0.9
UCB: 5.82
📋 0x
resolved
2 hypotheses
✓ Resolved

Are autophagy-lysosome defects primary drivers or downstream consequences in sporadic NDDs?

ParkinsonAlzheimerAre

While genetic evidence links autophagy dysfunction to neurodegeneration, the debate highlighted uncertainty about causality in sporadic diseases like

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 30% (3/10 entities, 9667.0 edges)
0.9
UCB: 5.82
📋 0x
partially_addressed
✓ Resolved

Extracellular vesicle biomarkers for early AD detection

CSFAlzheimerEVs

Extracellular vesicles (EVs), including exosomes and microvesicles, carry molecular cargo (proteins, miRNAs, lipids) from their cells of origin, inclu

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 30% (3/10 entities, 6026.0 edges)
🧬 Hypotheses working on this gap (22 total)
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes44% match
+18 more hypotheses
0.9
UCB: 5.82
📋 0x
partially_addressed
22 hypotheses
✓ Resolved

Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability

BrainAging

What gene expression changes in the aging mouse brain predict neurodegenerative vulnerability? Use Allen Aging Mouse Brain Atlas data. Cross-reference

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 4852.0 edges)
🧬 Hypotheses working on this gap (2 total)
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
0.9
UCB: 6.57
Repl: 0.75
📋 0x
partially_addressed
2 hypotheses
✓ Resolved

TREM2 agonism vs antagonism in DAM microglia

TREM2DAM

The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial rem

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 67% (2/3 entities, 3833.0 edges)
0.9
UCB: 5.82
📋 0x
resolved
24 hypotheses
✓ Resolved

Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability

BrainAging

What gene expression changes in the aging mouse brain predict neurodegenerative vulnerability? Use Allen Aging Mouse Brain Atlas data. Cross-reference

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 20% (2/10 entities, 4852.0 edges)
🧬 Hypotheses working on this gap (2 total)
Selective Neuronal Vulnerability Network TargetingCell-type specific vulnerability markers27% match
0.9
UCB: 6.65
Repl: 0.83
📋 0x
resolved
2 hypotheses
✓ Resolved

What evidence supports Cdk5 activation as THE primary cause of AD versus other established mechanisms?

Cdk5Alzheimer

The abstract claims Cdk5 activation is the primary cause of AD, contradicting the established multifactorial etiology involving amyloid plaques, tau t

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 18% (2/10 entities, 5910.0 edges)
0.9
UCB: 5.81
📋 0x
partially_addressed
✓ Resolved

APOE4 structural biology and therapeutic targeting strategies

APOE4APOE3

APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid binding and amyloid clearance.

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 67% (2/3 entities, 2258.0 edges)
0.9
UCB: 5.81
📋 0x
partially_addressed
16 hypotheses
✓ Resolved

Blood-brain barrier transport mechanisms for antibody therapeutics

BBBLRP1

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or n

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 40% (2/5 entities, 1801.0 edges)
🧬 Hypotheses working on this gap (10 total)
+6 more hypotheses
0.9
UCB: 5.81
📋 0x
partially_addressed
10 hypotheses
✓ Resolved

Do tau strains or regional cellular environments primarily drive PSP vs CBD pathological differences?

PSPCBD

The core debate question remains unresolved - whether intrinsic tau conformational strains or local brain microenvironments determine distinct astrocy

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 29% (2/7 entities, 399.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

What brain concentrations of SCFAs are achieved via oral probiotics and are they sufficient for therapeutic HDAC inhibition?

HDAC

The debate highlighted that while SCFAs can cross the blood-brain barrier, the actual brain concentrations reached through probiotic administration re

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 696.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the specific molecular mechanisms linking ADCY8 to spatial memory consolidation in hippocampal circuits?

ADCY8

While the debate proposes ADCY8-cAMP-PKA-CREB pathways, the exact molecular steps connecting ADCY8 activity to spatial memory encoding remain undefine

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 11% (1/9 entities, 19.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Which specific metabolic pathways in APOE4 microglia are causally linked to dysfunction versus compensatory?

APOE4

The debate identified glycolytic shifts and mTOR disruption but couldn't distinguish pathological changes from adaptive responses. The Skeptic noted t

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 12% (1/8 entities, 1636.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or exacerbate mitochondrial depletion in post-mitotic neurons?

PARKINPINK1

The debate revealed a critical gap: while PINK1/PARKIN deficiency correlates with excitatory neuron vulnerability, enhancing this pathway could trigge

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 33% (2/6 entities, 6646.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Investigate prion-like spreading of tau pathology through connected brain regions

Investigate prion-like spreading of tau pathology through connected brain regions

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
🧬 Hypotheses working on this gap (1 total)
Cholesterol-CRISPR Convergence Therapy for NeurodegenerHMGCR, LDLR, APOE regulatory regions30% match
0.9
UCB: 5.80
📋 0x
partially_addressed
1 hypotheses
✓ Resolved

Can TREM2 receptor switching from agonism to antagonism be achieved safely without tolerance or rebound inflammation?

TREM2

The stage-dependent strategy assumes sequential drug switching is feasible, but no evidence exists for safe receptor modulation reversal. The skeptic

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 3806.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How can senescent microglia be molecularly distinguished from beneficial activated microglia in vivo?

The debate revealed that microglial senescence markers are poorly defined compared to other cell types, making selective targeting impossible. Without

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

Prevotellaceae

The debate identified this correlation but the Skeptic highlighted the critical causality gap. Without resolving directionality, therapeutic intervent

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 3.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Are DNA methylation changes in neurodegeneration causal drivers or protective consequences of aging?

DNAAre

The debate highlighted this fundamental causality question that determines therapeutic strategy. The Skeptic noted methylation drift could be protecti

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 29% (2/7 entities, 5634.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do transferred mitochondria from diseased astrocytes carry pathological damage that could harm recipient neurons?

The debate highlighted that mitochondrial transfer could be therapeutic, but raised concerns about whether mitochondria from AD or other neurodegenera

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/5 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Can pathological vs physiological C1q tagging be distinguished at the molecular level?

C1q

The debate revealed a fundamental gap: whether disease-specific C1q conformational changes or co-localization patterns exist that could enable selecti

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 20.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do chronic stress granule inhibition strategies impair normal cellular stress responses in neurons?

RNA

The debate highlighted that RNA granules serve essential physiological functions, but it's unclear whether therapeutic dissolution would be neuroprote

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (1/6 entities, 5452.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the specific molecular mechanisms by which peripheral monocytes cross the BBB in AD?

BBB

The debate outlined peripheral immune involvement but failed to address the precise trafficking mechanisms and molecular signals that enable monocyte

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 141.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Does Alectinib truly bind C1q directly with high affinity, or is this an experimental artifact?

AlectinibC1q

The fundamental premise remains unvalidated despite extensive mechanistic speculation. Independent validation using purified proteins and orthogonal b

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 21.0 edges)
0.9
UCB: 4.37
📋 1x
investigating
✓ Resolved

Can circadian interventions selectively target microglia without affecting other brain cells or peripheral tissues?

The debate highlighted a critical cell-type specificity gap where no evidence exists for selective microglial targeting of circadian pathways. This fu

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

What is the therapeutic window between tau propagation inhibition and essential cellular function disruption?

ESCRTVAMP2

The debate highlighted that most promising targets (VAMP2, ESCRT, fascin-1) are essential for basic cellular processes, but the specific dosing/timing

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 22% (2/9 entities, 59.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

What are the specific design principles for small molecules that can selectively modulate pathological vs. physiological TDP-43 phase separation?

TDP-43

The debate identified that TDP-43 undergoes both normal and pathological phase separation, but no clear molecular criteria were established for design

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 14% (1/7 entities, 1771.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Does SYK activation provide neuroprotection or exacerbate neuroinflammation in established Alzheimer's disease?

TREM2SYKAlzheimer

The debate revealed fundamental uncertainty about whether enhancing TYROBP-SYK signaling would be beneficial or harmful, with existing drugs being SYK

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 30% (3/10 entities, 10068.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Neuroinflammation and microglial priming in early AD

APOE4TREM2AlzheimerNeuroinflammationDAMPs

How does microglial priming contribute to early Alzheimer's disease pathology? Focus on the mechanisms by which peripheral inflammation, aging, and ge

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 62% (5/8 entities, 16020.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
45 hypotheses
✓ Resolved

Do chaperones selectively recognize pathological vs physiological protein conformations?

HSP70HSP90

The debate revealed fundamental uncertainty about whether HSP70/HSP90 systems can distinguish pathological seeds from normal misfolded intermediates.

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 25% (2/8 entities, 1667.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

What is the therapeutic window between GCS inhibition efficacy and systemic toxicity in GBA-PD patients?

GCS

The debate identified systemic toxicity as a major concern for glucosylceramide synthase inhibitors, but no dose-response data exists for PD patients.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do different priming stimuli create distinct chromatin landscapes or converge on shared epigenetic states?

The debate presented conflicting evidence for convergent vs. stimulus-specific chromatin remodeling. The Skeptic noted that different tissues show dis

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/8 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Can IGFBPL1 therapeutics effectively cross the blood-brain barrier to reach CNS microglia?

IGFBPL1CNSBBB

The debate highlighted IGFBPL1's potential as a microglial master regulator but identified a critical gap in delivery mechanisms. Without resolving BB

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 30% (3/10 entities, 165.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in Alzheimer's progression? C1QA layer-specific gradient (0.646), TREM2 DAM upregulation (0.576), VGLUT1 excitatory neuron

APOE4VGLUT1C1QATREM2GFAP

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in Alzheimer's progression? C1QA layer-specific gradient (0.646), TREM2

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 78% (7/9 entities, 15569.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

How can subcellular compartmentalization defects be measured as biomarkers in living neurons?

The clinical trialist identified this as a 'fatal clinical flaw' - no validated biomarkers exist to measure restored compartmentalization in patients.

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do stellate neurons express unique α7 nicotinic receptor subtypes that could enable cell-type selective targeting?

The debate proposed α7-containing heteromers (α7β2) might be enriched in stellate neurons but provided no evidence. This is critical since previous br

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/5 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Does TFEB activation directly restore mutant GBA enzyme activity or only enhance lysosomal biogenesis?

GBATFEB

The debate identified this as a critical mechanistic gap - TFEB may increase lysosomal volume without addressing the fundamental GBA enzyme defect. Th

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 25% (2/8 entities, 4527.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

What are the optimal timing windows for TREM2 inhibition vs activation in Alzheimer's disease progression?

TREM2Alzheimer

The debate proposed temporal TREM2 modulation but couldn't define when to switch from inhibition to activation phases. This fundamental timing questio

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 25% (2/8 entities, 9701.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Does tau aggregation specifically cause PS externalization in vesicles independent of general cellular stress or apoptosis?

The debate revealed a fundamental gap in understanding whether tau pathology directly disrupts membrane asymmetry or if PS exposure is merely a conseq

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/8 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Investigate mechanisms of epigenetic reprogramming in aging neurons

Investigate mechanisms of epigenetic reprogramming in aging neurons

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
🧬 Hypotheses working on this gap (1 total)
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes24% match
0.9
UCB: 5.80
📋 0x
partially_addressed
1 hypotheses
✓ Resolved

Does tau aggregation specifically cause PS externalization in living cells versus general cellular stress responses?

The debate identified a critical gap in understanding whether PS exposure is tau-specific or a general stress marker. This distinction is essential fo

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

APOE4-driven lipid metabolism dysregulation in astrocytes and its role in AD

APOE4

APOE4 is the strongest genetic risk factor for late-onset AD. How APOE4 specifically disrupts lipid homeostasis in astrocytes, cholesterol transport,

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 33% (1/3 entities, 1636.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
19 hypotheses
✓ Resolved

Do migratory animals encode specific spatial locations epigenetically or rely on innate navigational instincts?

The debate highlighted a fundamental uncertainty about whether transgenerational migration routes involve learned spatial memories versus hardwired na

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/6 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Which specific post-translational modifications create druggable epitopes unique to pathological tau?

The debate was structured around this question but no literature was provided to address it. Identifying these modifications is critical for developin

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Which specific post-translational modifications distinguish pathological from physiological tau for therapeutic targeting?

The core research question was never addressed due to missing literature content. Identifying these specific modifications is critical for developing

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do tau-containing vesicles exhibit distinct surface glycosylation patterns compared to normal vesicles?

This fundamental question underlies all therapeutic hypotheses but lacks experimental evidence. The debate revealed this is a critical knowledge gap t

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/6 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do tau-specific HSP90 conformational states exist that differ from other client protein complexes?

HSP90

The debate hinged on whether HSP90 adopts unique conformations when bound to tau versus other clients, but no structural evidence was provided. This f

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 14% (1/7 entities, 532.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

LRRK2RAB10G2019S

The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification d

Strategic Value
Investigating this gap will generate new hypotheses and strengthen the knowledge graph.
KG Coverage: 33% (3/9 entities, 2754.0 edges)
0.9
UCB: 5.80
📋 0x
open

test

test

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/0 entities, 0 edges)
0.9
UCB: 4.37
📋 1x
investigating
✓ Resolved

Do astrocytes functionally express TRIM46, and can PKCα phosphorylate it to drive TNT formation?

P2X7

The P2X7 hypothesis relies on TRIM46-mediated actin polymerization in astrocytes, but TRIM46 is established as neuronal-specific for microtubule organ

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 11% (1/9 entities, 384.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

test debate

test debate [TARGET_ARTIFACT type=experiment id=exp-123]

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/1 entities, 0 edges)
0.9
UCB: 4.37
📋 1x
investigating
✓ Resolved

Does APOE4 drive tau propagation

APOE4

Does APOE4 drive tau propagation [TARGET_ARTIFACT type=hypothesis id=TEST-123]

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 25% (1/4 entities, 1636.0 edges)
0.9
UCB: 4.37
📋 1x
investigating
✓ Resolved

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzheimer's disease progression?

TREM2Alzheimer

The debate proposed biphasic TREM2 modulation but couldn't define when to switch from inhibition to activation. The Skeptic noted AD lacks discrete te

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 25% (2/8 entities, 9701.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protec

ALSDAM

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacolo

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 50% (2/4 entities, 8660.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

RNA binding protein dysregulation across ALS FTD AD

RNAALSFTD

RNA binding protein dysregulation across ALS FTD AD

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 100% (3/3 entities, 14759.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Investigate mechanisms of epigenetic reprogramming in aging neurons

Investigate mechanisms of epigenetic reprogramming in aging neurons

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
resolved
✓ Resolved

Does C1q function differ based on subcellular localization or binding partner identity?

C1q

The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depe

Strategic Value
Investigating this gap will generate new hypotheses and strengthen the knowledge graph.
KG Coverage: 12% (1/8 entities, 20.0 edges)
0.9
UCB: 5.80
📋 0x
open

Is ferroptosis the primary driver of motor neuron death in ALS or an epiphenomenon of terminal cellular collapse?

ALS

The debate highlighted compelling correlative evidence for ferroptosis markers in ALS tissues, but causality remains unestablished. This fundamental q

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 8633.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Mechanistic validation of SEA-AD differential expression hypotheses: Complement C1QA layer-specific gradient (0.646), TREM2 DAM upregulation (0.576), VGLUT1 excitatory neuron loss (0.567), APOE4 glial

GFAPAlzheimerDAMAPOE4Complement

Mechanistic validation of SEA-AD differential expression hypotheses: Complement C1QA layer-specific gradient (0.646), TREM2 DAM upregulation (0.576),

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 42% (8/10 entities, 16991.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methylation changes, histone modification dynamics, chromatin remodeling, and partial reprogramming approaches (e.g.,

DNA

Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methylation changes, histone modification dynamics, chromatin remod

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 25% (1/4 entities, 5631.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Investigate mechanisms of epigenetic reprogramming in aging neurons

Investigate mechanisms of epigenetic reprogramming in aging neurons [TARGET_ARTIFACT type=analysis id=SDA-2026-04-04-gap-epigenetic-reprog-b685190e]

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/3 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methylation changes, histone modification dynamics, chromatin remodeling, and partial reprogramming approaches (e.g.,

DNA

Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methylation changes, histone modification dynamics, chromatin remod

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 25% (1/4 entities, 5631.0 edges)
0.9
UCB: 5.80
📋 0x
resolved
✓ Resolved

What is the optimal BBB opening duration and spatial precision to maximize therapeutic benefit while minimizing neurotoxicity?

BBB

The debate highlighted focused ultrasound as most feasible but didn't resolve critical dosing parameters. The temporal window for BBB opening and prec

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (1/6 entities, 141.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease

ParkinsonLPSTMAO

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signal

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 60% (3/5 entities, 3804.0 edges)
0.9
UCB: 4.37
📋 1x
investigating
✓ Resolved

Selective vulnerability of entorhinal cortex layer II neurons in AD

Why do entorhinal cortex layer II stellate neurons die first in AD? Their unique electrophysiological properties, grid cell function, and high metabol

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/3 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
7 hypotheses
✓ Resolved

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationship between sleep disorders (particularly circadian rhythm disruption and impaired glymphatic clearan

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationship between sleep disorders (particularly circadian

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
10 hypotheses
✓ Resolved

Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retention at the ER membrane?

APOE4SREBP2

The theorist proposed APOE4 lipidation status affects SREBP2 processing, but the skeptic identified a critical mechanistic gap - no established pathwa

Strategic Value
Investigating this gap will generate new hypotheses and strengthen the knowledge graph.
KG Coverage: 17% (2/10 entities, 2046.0 edges)
0.9
UCB: 5.80
📋 0x
open

Tau propagation mechanisms and therapeutic interception points

Tau

What are the mechanisms by which tau pathology spreads through connected brain regions via prion-like transmission, trans-synaptic transfer, and extra

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 50% (1/2 entities, 166.0 edges)
🧬 Hypotheses working on this gap (11 total)
Cholesterol-CRISPR Convergence Therapy for NeurodegenerHMGCR, LDLR, APOE regulatory regions30% match
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes30% match
+7 more hypotheses
0.9
UCB: 5.80
📋 0x
partially_addressed
11 hypotheses
✓ Resolved

Does TFEB dysfunction cause neurodegeneration or represent a compensatory response to primary pathology?

TFEB

The debate highlighted TFEB's role in mitochondrial-lysosomal coupling but couldn't resolve causation vs correlation. This distinction is critical for

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 12% (1/8 entities, 2951.0 edges)
🧬 Hypotheses working on this gap (10 total)
+6 more hypotheses
0.9
UCB: 5.80
📋 0x
partially_addressed
10 hypotheses
✓ Resolved

Does structural 'normalization' of APOE4 domain interactions actually improve amyloid clearance function?

APOE4

The debate assumed that correcting APOE4's aberrant domain interactions would restore function, but this wasn't validated. The Skeptic noted that stru

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 1636.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-specific synaptic vulnerability in Alzheimer's progression? C1QA layer-specific gradient (0.646), TREM2 DAM upregulation (0.5

APOE4VGLUT1C1QATREM2GFAP

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-specific synaptic vulnerability in Alzheimer's progression? C1QA layer-spec

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 64% (7/10 entities, 15569.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo?

SCFA

The debate highlighted that most SCFA studies use pharmacological doses (mM) rather than physiologically achievable concentrations. This dose-response

Strategic Value
Investigating this gap will generate new hypotheses and strengthen the knowledge graph.
KG Coverage: 12% (1/8 entities, 3.0 edges)
0.9
UCB: 5.80
📋 0x
open

What determines blood-brain barrier penetration kinetics for specialized pro-resolving mediators?

BBB

The debate highlighted BBB penetration as a major hurdle for SPM therapeutics but provided no mechanistic understanding of transport barriers. This kn

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 141.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the therapeutic window between insufficient and toxic levels of TDP-43 arginine methylation?

TDP-43

The debate highlighted a critical dosing paradox where both hypo- and hypermethylation could be harmful, but no clear boundaries were established. Thi

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1771.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do circadian disruptions cause neurodegeneration or result from it?

The debate highlighted that speech timing and sleep changes could reflect circadian dysfunction, but causality remains unresolved. Determining whether

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/5 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the relative contribution of connexin-43 gap junctions vs tunneling nanotubes to mitochondrial transfer?

The debate revealed conflicting evidence about whether connexin-43 mediates mitochondrial transfer through gap junctions or tunneling nanotubes. This

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations?

SCFASDA-2026-04-01-gap-20260401-225155

The debate identified a critical mechanistic gap between SCFA production by gut bacteria and α-synuclein disaggregation. While SCFAs cross the blood-b

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 25% (2/8 entities, 19.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Does human glymphatic function show clinically relevant circadian variation like rodent models?

The debate highlighted major uncertainty about whether rodent glymphatic findings translate to humans, with conflicting evidence on circadian patterns

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Is HCN1 dysfunction causal or protective in EC layer II neurodegeneration?

HCN1

The debate revealed conflicting evidence about whether HCN1 downregulation drives neuronal death or represents a protective response to excessive exci

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 347.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What physicochemical properties determine selective protein recruitment vs exclusion from 53BP1 condensates?

The debate identified this as the core knowledge gap but provided no mechanistic insights. Understanding these selectivity rules is essential for pred

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Does DNAJB6 directly inhibit cross-seeding between tau, α-synuclein, and TDP-43 or only homologous aggregation?

TDP-43DNAJB6

The debate revealed that DNAJB6 evidence is limited to polyglutamine aggregation, with no direct testing of heterologous cross-seeding inhibition. Thi

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 2242.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-synuclein aggregation in humans?

CNS

The debate showed compelling in vitro and C. elegans evidence for cross-seeding, but the skeptic raised critical concerns about blood-brain barrier pe

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 8.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What determines the temporal transition from protective to pathological stress granules in neurodegeneration?

The debate revealed that stress granules can be both neuroprotective and pathological, but the molecular switches governing this transition remain unk

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationship between sleep disorders (particularly circadian rhythm disruption and impaired glymphatic clearan

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationship between sleep disorders (particularly circadian

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
resolved
10 hypotheses
✓ Resolved

What is the actual quantitative contribution of FcRn-mediated transcytosis to BBB antibody transport in humans?

FcRnBBB

The debate revealed conflicting estimates ranging from <5% to 20% for FcRn's role in BBB transport, with species differences unresolved. This fundamen

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 18% (2/10 entities, 154.0 edges)
0.9
UCB: 5.80
📋 0x
partially_filled
✓ Resolved

Are age-related DNA methylation changes protective adaptations or pathological drivers in neurodegeneration?

DNAAre

The debate raised this fundamental question but provided no resolution. The Skeptic suggested methylation changes might be protective rather than path

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 5634.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

C1q

The debate revealed conflicting evidence about C1q's role - some studies show it drives synaptic loss while others suggest it facilitates protective a

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 20.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the molecular determinants that control directional mitochondrial transfer from astrocytes to neurons?

The debate proposed bioenergetic gradients drive transfer but didn't identify the specific molecular sensors or trafficking machinery that determines

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the high-resolution structure of the APOE4 hinge region and its role in pathological domain interaction?

APOE4

The debate revealed that no high-resolution structure exists for the critical hinge region (residues 130-160) that allegedly mediates APOE4's patholog

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1636.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Can biased TREM2 agonists selectively activate DAP12-SYK-PI3K without triggering ERK-AP1 inflammatory pathways?

TREM2

The theorist proposed this novel approach to enable safe agonism across disease stages, but no evidence exists for such selective pathway activation.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 3806.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the temporal sequence of sleep disruption versus amyloid-beta accumulation in preclinical neurodegeneration?

The debate highlighted the bidirectional relationship between sleep and neurodegeneration but failed to establish which occurs first in disease progre

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do SPM receptors undergo desensitization with chronic agonist treatment, preventing therapeutic priming?

GPCRGPR32FPR2ALX

The debate highlighted receptor desensitization as a critical concern for SPM receptor priming therapy, but no definitive data exists on whether ALX/F

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 40% (4/10 entities, 40.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the molecular signatures that distinguish protective vs. harmful microglial states across AD, PD, and ALS?

ALS

The debate transcript shows incomplete information exchange, suggesting this fundamental question about microglial phenotyping remains unresolved. Wit

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 8633.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What specific gene expression signatures in aging mouse brain predict human AD vulnerability?

Brain

The debate was structured to identify aging-neurodegeneration mechanisms using Allen Brain Atlas data cross-referenced with human AD datasets, but no

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 36.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How can Allen Aging Mouse Brain Atlas data be systematically cross-referenced with human AD datasets to identify conserved vulnerability markers?

BrainAging

The debate failed to produce any actual hypotheses despite this being the core research question. The methodological approach for integrating mouse ag

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 4852.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What specific gene expression signatures in aging mouse white matter predict human AD vulnerability?

The debate initiated investigation into white matter aging and myelin changes but was incomplete. The critical gap remains in identifying which molecu

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/6 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Which specific cell types show greatest vulnerability in AD based on SEA-AD transcriptomic analysis?

Brain

The debate was initiated to analyze cell-type-specific vulnerability using SEA-AD data and Allen Brain Cell Atlas evidence, but no actual analysis or

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 8% (1/10 entities, 36.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Which specific aging-related gene expression changes in mouse brain predict human AD vulnerability?

BrainAging

The debate aimed to cross-reference Allen Aging Mouse Brain Atlas data with human AD datasets but never produced the actual comparative analysis. This

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (2/10 entities, 4852.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How can circuit-level neurodegeneration mechanisms be identified without complete debate analysis?

The debate transcript shows incomplete analysis where the Theorist reached maximum tool rounds before presenting hypotheses, and subsequent participan

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/8 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the optimal timing windows for TREM2 agonism vs antagonism across disease progression stages?

TREM2

The debate highlighted that TREM2 therapeutic targeting remains contested across disease stages, but no clear framework exists for when to activate ve

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 3806.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How can CRISPR systems achieve persistent therapeutic effects while avoiding chronic immune responses to Cas proteins in the CNS?

CRISPRSDA-2026-04-02-gap-crispr-neurodegeneration-20260402CNS

The debate highlighted that long-term CRISPR expression triggers immune responses, but epigenetic therapies require persistence. No clear solution exi

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 33% (3/9 entities, 36.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Can P16INK4A expression reliably distinguish harmful from beneficial senescent microglia in neurodegeneration?

P16INK4A

The debate proposed P16INK4A-guided targeting but the Skeptic noted microglia exist in complex activation states that don't fit binary classifications

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 46.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the atomic-resolution structure of K280-acetylated tau and how does it template aggregation?

The debate proposed K280 acetylation creates a β-sheet nucleation interface but lacks structural evidence. Without atomic-level understanding of how a

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/9 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do oligodendrocytes require DNA repair enhancement or inhibition for neuroprotection in AD?

DNAPARP

The debate revealed conflicting therapeutic approaches - enhancing DNA repair versus using PARP inhibitors. The mechanistic direction remains unresolv

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 29% (2/7 entities, 5639.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do tau aggregates represent protective responses or primary pathogenic drivers in vulnerable neuronal subtypes?

The debate highlighted fundamental disagreement about tau's role - whether aggregation causes neuronal death or represents a compensatory mechanism. T

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/6 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving beneficial microglial functions?

P2RX7

The debate highlighted P2RX7's dual role in both harmful exosome secretion and beneficial microglial responses. The critical therapeutic window betwee

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (1/6 entities, 634.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Is myelin loss in AD causal or an adaptive response to neuronal damage?

The debate raised conflicting views on whether myelin restoration would be beneficial or harmful in AD. The skeptic suggested myelin loss could be ada

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/5 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

How can functional hyperconnectivity patterns distinguish compensatory mechanisms from early pathological markers in AD?

The debate framework identified functional hyperconnectivity as potentially representing either compensatory responses or early pathological changes,

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Does CXCL10 inhibition compromise CNS immune surveillance during chronic treatment?

CNSCXCL10

The debate highlighted major safety concerns about blocking CXCL10, particularly increased infection susceptibility, but no long-term studies exist. T

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 961.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What validated biomarkers can determine optimal TFEB activity windows during disease progression?

TFEB

The debate proposed temporal TFEB modulation but identified no validated biomarkers to guide when TFEB should be enhanced versus inhibited. This repre

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 2951.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What distinguishes truly senescent brain cells from merely dysfunctional reactive glia?

Multiple

Multiple participants noted the conflation of cellular dysfunction with senescence, but specific biomarkers to differentiate senescent from reactive a

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (1/6 entities, 10.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What is the optimal ketone dosing threshold to avoid metabolic steal syndrome while preserving neuroprotection?

The debate identified that ketone levels >2.0 mM may disrupt astrocyte-neuron metabolic coupling, but the precise dose-response relationship remains u

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Which neural cell types exhibit the most pronounced gene expression alterations in neurodegeneration?

The debate generated therapeutic hypotheses targeting different cell types but never resolved the fundamental question of which populations show the s

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?

O-GlcNAcylation

The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which modifications can be selectively targeted wit

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 9% (1/10 entities, 5.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

What are the conserved secondary structures in dilncRNAs that enable selective therapeutic targeting?

ASO

The ASO therapeutic hypothesis assumes dilncRNAs have targetable conserved structures, but the skeptic noted this is unproven. Without structural char

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 11% (1/9 entities, 5.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
✓ Resolved

Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or cause iatrogenic mitophagy toxicity in AD?

PARKINPINK1

The debate revealed a critical gap: while excitatory neurons show mitochondrial dysfunction signatures, it's unknown whether enhancing PINK1/PARKIN ac

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 25% (2/8 entities, 6646.0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

Neuroinflammation and microglial priming in early Alzheimer's Disease

CSFGFAPAlzheimerNeuroinflammationTNF

Investigate the role of neuroinflammation and microglial priming in the earliest stages of Alzheimer's Disease pathology, before clinical symptoms eme

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 73% (10/10 entities, 32174.0 edges)
0.9
UCB: 5.80
📋 0x
partially_addressed
65 hypotheses
✓ Resolved

Which cell-type vulnerability signatures from SEA-AD single-cell data represent causal mechanisms versus secondary consequences of neurodegeneration?

All participants agreed that transcriptomic vulnerability signatures don't establish causation. Distinguishing primary vulnerability mechanisms from d

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.80
📋 0x
investigating
✓ Resolved

epigenetic reprogramming aging neurons

epigenetic reprogramming aging neurons

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/0 entities, 0 edges)
🧬 Hypotheses working on this gap (1 total)
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes24% match
0.9
UCB: 5.80
📋 0x
partially_addressed
1 hypotheses
✓ Resolved

What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effects against dementia?

SemaglutideTirzepatideGLP-1RAObesityNeurodegeneration

The study demonstrates significant reduction in dementia risk (HR 0.63) with GLP-1RA treatment, but the underlying neuroprotective mechanisms remain u

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 44% (8/10 entities, 12332.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How do P/Q channel deficits paradoxically increase thalamic excitability despite impairing neurotransmitter release?

Neuron

The abstract describes a counterintuitive finding where loss-of-function P/Q mutations that impair transmitter release somehow increase rather than de

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 4528.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What signals trigger microglia to specifically recognize and phagocytose LC axons in early AD?

Alzheimer

The study shows that OB microglia phagocytose LC axons before amyloid plaque formation, but the molecular signals that mark these axons for destructio

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 9% (1/10 entities, 5895.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

TAM

The finding that Mertk/Axl deficiency increases viral susceptibility contradicts the established paradigm that TAM receptors dampen antiviral immunity

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 1.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How does PIKFYVE inhibition activate unconventional protein clearance via exocytosis?

ALSPIKFYVE

The abstract describes a novel mechanism where PIKFYVE inhibition triggers exocytosis of aggregation-prone proteins, but the molecular pathway is not

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 8763.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms enable functional recovery and muscle re-innervation after motor neuron loss in ALS/FTLD?

ALSTDP-43FTLD

The study shows dramatic functional recovery and muscle re-innervation after cytoplasmic TDP-43 clearance, even following motor neuron death. The cell

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 30% (3/10 entities, 10976.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms drive the transition from acute to persistent neuroinflammation in pediatric TBI?

BrainTBI

The abstract shows that acute neuroinflammation becomes persistent with a specific transcriptomic signature, but the mechanistic drivers of this trans

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 244.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Does TRT-induced erythrocytosis actually increase venous thromboembolism risk in clinical practice?

TestosteroneAgingMaleTherapyReplacement

Despite FDA warnings and a 315% increased erythrocytosis risk with TRT, the association between elevated hematocrit and actual VTE events remains inco

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 26% (5/10 entities, 4840.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What are the specific circulating factors in exercise-conditioned plasma that mediate neuroprotection against POCD?

TrkBCCSBDNFPOCD

The study demonstrates that exercise-conditioned plasma transfers cognitive benefits, but the identity of the active circulating factors remains unkno

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 33% (4/10 entities, 5020.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding to pTau?

Gal3Galectin-3

The abstract shows that Gal3 binding to pTau greatly enhances tau fibrillation, but the specific molecular interactions and structural changes driving

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 8.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What genetic risk factors predispose individuals to developing CTE following repetitive brain trauma?

BrainCTE

The abstract explicitly states the critical need to identify genetic risk factors for CTE, but these remain unknown. Understanding genetic susceptibil

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 38.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk?

LOADABCA7

The abstract shows V1613M variant reduces amyloid plaques and damage in 5xFAD mice, yet ABCA7 loss-of-function mutations increase LOAD risk. This appa

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 610.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimmunity in healthy individuals?

AQP4

The title suggests B cells actively maintain tolerance to AQP4, but the specific molecular mechanisms by which B cells prevent anti-AQP4 autoimmunity

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1872.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How does APOE4's beneficial immune function reconcile with its established role as the strongest AD risk factor?

APOE4APOE

This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detri

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 22% (2/9 entities, 6645.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms cause iPLA2β deficiency to specifically damage mitochondrial inner membranes?

NeuropathologyPLA2G6

The abstract shows that damaged mitochondrial inner membranes appear early in PLA2G6 KO mice, but the specific biochemical pathways linking phospholip

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (2/10 entities, 224.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How does pericyte senescence mechanistically promote glioma cell growth and invasion?

The abstract reports that pericyte senescence contributes to glioma growth and invasion, but the specific molecular mechanisms linking senescent peric

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/8 entities, 0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodegeneration?

OxPC

The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendrocytes, but the specific neutralization mechanisms are not explained. U

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 20.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondrial depletion in tauopathy?

PRKN

The abstract reveals an unexpected contradiction where PRKN activation, normally considered neuroprotective through damaged mitochondria removal, actu

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 10% (1/10 entities, 1687.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy formation?

CAA

The study demonstrates that apoE is absolutely required for CAA development, as apoE knockout completely prevents CAA formation. However, the specific

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 9% (1/10 entities, 1.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

What molecular mechanisms link elevated sphingomyelin synthase activity to increased amyloid-beta generation?

APPSGMS1

The study demonstrates that SGMS1 elevation correlates with increased Aβ and that SGMS inhibition reduces Aβ production, but the specific biochemical

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 4796.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

How does SYNGAP1, a 'synaptic' protein, function in pre-synaptic radial glia cells during neurogenesis?

ASDSYNGAP1

This study reveals SYNGAP1 expression and function in radial glia before synaptogenesis, contradicting its classification as purely a synaptic protein

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 25.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in neurons?

PSEN2

The study shows PSEN2 is essential in cortical and dopaminergic neurons and regulates αS expression, but the molecular mechanism linking PSEN2 to synu

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 11% (1/9 entities, 852.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What upstream mechanisms trigger p53 activation specifically in response to poly(PR) dipeptide repeats?

C9orf72

The abstract shows p53 is a central regulator of C9orf72-mediated neurodegeneration but doesn't explain how poly(PR) specifically activates p53. Under

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 11% (1/9 entities, 84.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

What is the molecular mechanism by which oligodendroglial MCT1 disruption causes axon damage and neuron loss?

MCT1

The study shows that MCT1 disruption leads to axon degeneration and neuron death, but the specific molecular pathways linking lactate transport dysfun

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 11% (1/9 entities, 86.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity lead to better patient outcomes?

IDHIDH1IDH2

The abstract shows that IDH mutations reduce protein enzymatic activity yet paradoxically correlate with improved prognosis. This counterintuitive fin

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 27% (3/10 entities, 690.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neurodegeneration?

CRISPRKCNJ2

The study identifies KCNJ2 as a therapeutic target through CRISPR screening but doesn't explain the mechanistic pathway by which this mechanosensory c

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 30.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms mediate SPP1-induced microglial phagocytic activation and synaptic targeting?

AlzheimerSPP1

The study shows SPP1 from perivascular cells drives microglial synaptic engulfment, but the specific receptors, signaling pathways, and molecular casc

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 17% (2/10 entities, 6350.0 edges)
0.9
UCB: 5.79
📋 0x
resolved
✓ Resolved

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenesis?

FUSALSFTDTAZ

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate dynamics, but doesn't address how FUS mutations in ALS/FTD might disr

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 36% (4/10 entities, 11094.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What specific molecular mechanisms link APOE4 to cholesterol dysregulation in oligodendrocytes?

APOE4

The abstract identifies APOE4's primary effect on oligodendrocyte cholesterol metabolism but doesn't explain the mechanistic pathway. Understanding th

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1636.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanism causes VCP mutations to trigger aberrant HIF-1α activation under normoxic conditions?

ALSVCP

The study shows VCP-mutant astrocytes exhibit hypoxia response activation without actual hypoxia, but the mechanistic link between VCP dysfunction and

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 15% (2/10 entities, 9627.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why does Metformin fail to delay CJD progression despite improving anti-aging hallmarks like Nano-PSO?

NeurobiologyCreutzfeldt-JakobCOXAMPKNrf2

Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and inflammation, yet only Nano-PSO delayed disease progression. This discordan

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 47% (8/10 entities, 5009.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Does clusterin exacerbate or protect against neuronal death in neurodegeneration?

Clusterin

The abstract reveals contradictory evidence where clusterin is proposed as a protective chaperone protein, yet knockout studies show it exacerbates ne

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 2.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers despite reducing iron levels?

ParkinsonHFE

The study shows deferiprone rescues wild-type cells but exacerbates toxicity in H63D HFE cells, contradicting the assumption that iron reduction is un

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 3811.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

Why does PGC-1α overexpression paradoxically increase MPTP toxicity despite enhancing antioxidant defenses?

MPTPBdnf

PGC-1α is known to enhance mitochondrial function and antioxidant responses, yet overexpression increased susceptibility to MPTP-induced neuronal deat

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (2/10 entities, 657.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple AD risk receptors?

TREM2CR3AlzheimerTYROBPCD33

The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 38% (5/10 entities, 10860.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What are the physiological functions of BACE1 beyond APP processing that could cause side effects from therapeutic inhibition?

BACE1AlzheimerAPP

The abstract identifies BACE1 as an attractive drug target but doesn't address its normal physiological roles. Understanding these functions is critic

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 30% (3/10 entities, 11999.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

How does engineered C. butyricum cross the blood-brain barrier to directly bind GLP-1 receptors?

ProbioticsNeurodegenerationA53TSenescenceAstrocyte

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 receptors, but this is mechanistically implausible for a bacterial organism.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 35% (7/10 entities, 10022.0 edges)
0.9
UCB: 4.36
📋 1x
investigating
✓ Resolved

What molecular mechanisms determine whether reactive astrocytes adopt neurotoxic A1 vs neuroprotective A2 phenotypes?

Brain

The abstract describes astrocyte phenotypic heterogeneity (A1/A2) but doesn't explain the mechanistic switches governing this critical fate decision.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 36.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and cellular function?

OPTNALSRab8aOptineurin

The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper domain but don't fully explain how these mutations mechanistically lead

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 25% (4/10 entities, 11201.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How do the seven novel ALS genes function in animal models to cause neurodegeneration?

NEK1ALSCHCHD10TBK1MATR3

The authors explicitly state that the effects of these novel genes (MATR3, CHCHD10, TBK1, TUBA4A, NEK1, C21orf2, and CCNF) have not yet been investiga

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 35% (6/10 entities, 10459.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why does autophagy inhibition improve neuronal survival when autophagy is typically neuroprotective?

Autophagy

This finding contradicts the established paradigm that autophagy is generally protective in neurons and neurodegenerative diseases. The counterintuiti

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 5943.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis capacity?

HomeostasisDevelopmentNeurodegenerationHDAC1Histone

While the study shows HDAC1/2 deletion improves amyloid clearance and cognition, the specific epigenetic and transcriptional changes that enhance phag

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 39% (7/10 entities, 8936.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms drive neuron-to-glioma synapse formation in high-neural glioblastomas?

The study demonstrates that high-neural glioblastoma cells form synapses with neurons both in vitro and in vivo, but the underlying molecular mechanis

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms mediate HDAC9's effects on Aβ deposition and synaptic function?

HDAC9Alzheimer

The abstract shows HDAC9 overexpression reduces Aβ deposition and improves synaptic deficits, but the underlying molecular pathways are not explained.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (2/10 entities, 5933.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

How do oligodendrocytes initiate neuroinflammation in PD when microglia are traditionally considered primary drivers?

ParkinsonOligodendrocytes

This study identifies oligodendrocytes as drivers of neuroinflammation in PD, contradicting the established paradigm that microglia are the primary ne

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 3817.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in Parkinson's patients?

AtremorineParkinson

The abstract reports extraordinary dopamine increases (>500-fold in drug-free patients) but provides no mechanistic explanation for how Atremorine ach

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (2/10 entities, 3787.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients?

TBICBP

The observation that salsalate and diflunisal decrease both AD and TBI incidence suggests these drugs may prevent injury occurrence, not just treat co

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 314.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

What molecular mechanisms underlie the dose-dependent protective effects of the R136S mutation against APOE4 toxicity?

APOE4TauR136SAPOE-R136S

The study shows homozygous R136S fully rescues APOE4-driven pathology while heterozygous provides only partial protection, but the mechanistic basis f

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 33% (4/10 entities, 1806.0 edges)
0.9
UCB: 5.79
📋 0x
investigating
✓ Resolved

Microglia-astrocyte crosstalk amplification loops in neurodegeneration

TNFC1qMicroglia

Microglia activate astrocytes via IL-1alpha/TNF/C1q, and reactive astrocytes feed back to microglia via complement/chemokines.

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 60% (3/5 entities, 8165.0 edges)
0.9
UCB: 5.79
📋 0x
partially_addressed
15 hypotheses
✓ Resolved

What biomarkers can reliably detect microglial priming states in living patients before neurodegeneration?

The debate focused on therapeutic targets but did not address how to identify patients in the optimal treatment window. Without reliable biomarkers fo

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 5.78
📋 0x
partially_addressed
✓ Resolved

What amyloid threshold level is required for optimal clinical benefit in early AD?

AlzheimerDiseaseAmyloidDonanemab

While the study demonstrates dose-response relationships between amyloid levels and outcomes, it doesn't establish specific threshold values for clini

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 17% (4/10 entities, 7800.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

What determines the GPX4/ACSL4 balance that switches microglia from protective to ferroptotic states?

ACSL4GPX4

While ACSL4-driven ferroptosis was strongly supported, the molecular triggers that tip the balance from protective GPX4 activity to pathological ACSL4

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 18% (2/10 entities, 3090.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

How do sphingomyelin/ceramide ratios specifically regulate BACE1 clustering and activity in synaptic vs non-synaptic lipid rafts?

BACE1

The debate established that ceramide accumulation affects amyloid-β processing but didn't resolve the spatial specificity of this mechanism. Understan

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1515.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Synaptic pruning by microglia in early AD

Synaptic pruning by microglia in early AD

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 0% (0/1 entities, 0 edges)
🧬 Hypotheses working on this gap (3 total)
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes30% match
0.9
UCB: 5.78
📋 0x
partially_addressed
3 hypotheses
✓ Resolved

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloendothelial clearance?

CNSBBBEVs

All participants identified brain delivery as a critical barrier, but no mechanism was proposed for overcoming BBB limitations or avoiding systemic cl

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 27% (3/10 entities, 152.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

GBA-alpha-synuclein bidirectional loop in Parkinson's

ParkinsonGBA

GBA mutations impair lysosomal function and promote alpha-synuclein aggregation, but alpha-synuclein itself inhibits GBA activity. The therapeutic imp

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 50% (2/4 entities, 5345.0 edges)
🧬 Hypotheses working on this gap (3 total)
Multi-Modal CRISPR Platform for Simultaneous Editing anDisease-causing mutations with integrated reporters20% match
0.9
UCB: 5.78
📋 0x
partially_addressed
3 hypotheses
✓ Resolved

Does LRRK2's role as a lysosomal volume sensor explain the pathogenic mechanism of disease-linked LRRK2 mutations?

ParkinsonLRRK2

While the study establishes LRRK2 as a lysosomal swelling sensor and notes that lysosomal swelling occurs in LRRK2-linked diseases, it doesn't directl

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 20% (2/10 entities, 6402.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Why have numerous phase 3 clinical trials failed despite advances in understanding AD pathobiology?

DiseaseAlzheimer

There's a clear disconnect between improved mechanistic understanding of AD and therapeutic success, with continued phase 3 trial failures. This trans

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 15% (2/10 entities, 5912.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Does TRPML1 enhancement cause therapeutic benefit or paradoxical lysosomal dysfunction in vivo?

TRPML1

The debate revealed conflicting evidence about whether TRPML1 activation rescues or worsens lysosomal function, with studies showing both therapeutic

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 193.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Trans-synaptic tau spreading and propagation mechanisms in AD

MechanismsAlzheimerTau

Tau pathology spreads through synaptically connected brain regions in Alzheimer disease following a stereotyped anatomical pattern. Mechanisms of tran

Strategic Value
Investigation complete—insights integrated into hypothesis rankings.
KG Coverage: 75% (3/4 entities, 6068.0 edges)
🧬 Hypotheses working on this gap (11 total)
Epigenetic Memory Reprogramming for Alzheimer's DiseaseBDNF, CREB1, synaptic plasticity genes44% match
+7 more hypotheses
0.9
UCB: 5.78
📋 0x
partially_addressed
11 hypotheses
✓ Resolved

Is APOE4's reduced lipid binding pathogenic or a compensatory evolutionary adaptation?

APOE4

The skeptic raised evidence that APOE4 carriers show enhanced cholesterol synthesis, suggesting the lipid binding deficit may be compensatory rather t

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 1636.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

What are the precise temporal dynamics of astrocyte ketone production decline during neurodegeneration progression?

The debate identified a critical therapeutic window when astrocytic ketone production declines but neurons retain oxidation capacity, but the exact ti

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/7 entities, 0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

What are the specific PTM changes in synaptic vesicle proteins during early AD pathogenesis?

The debate framework identified synaptic vesicle protein modifications as critical but no specific hypotheses were evaluated. Understanding which phos

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 0% (0/8 entities, 0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD pathogenesis?

Alzheimer

The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presume

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 11% (1/9 entities, 5895.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

What is the temporal sequence of TREM2 signaling transition from protective to inflammatory during aging?

TREM2

While TREM2 was identified as critical for microglial senescence, the debate lacked fine-grained temporal data on when and how TREM2 signaling shifts

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 3806.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Do CXCL10-recruited CD8+ T cells provide neuroprotection or cause damage in aging white matter?

CD8

The debate revealed contradictory evidence about CD8+ T cell roles in neurodegeneration, with some studies showing protection and others showing harm.

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 12% (1/8 entities, 1156.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved

Are age-related static epigenetic patterns pathogenic or protective compensatory mechanisms?

Are

The debate assumed static 5-hydroxymethylcytosine patterns in aging neurons are harmful, but the skeptic raised the possibility these could be stabili

Strategic Value
Active agent debates are generating evidence and testable claims.
KG Coverage: 14% (1/7 entities, 3.0 edges)
0.9
UCB: 4.35
📋 1x
investigating
✓ Resolved